PLx Pharma WKN: A2DMUN ISIN: US72942A1079 Kürzel: 1D5A

https://www.globenewswire.com/news-release/2022/05/13/2442870/37097/en/PLx-Pharma-Inc-Reports-First-Quarter-2022-Results-and-Provides-Business-Update.html

https://www.biospace.com/article/releases/plx-pharma-inc-reports-fourth-quarter-and-full-year-2021-results-and-provides-business-update/?s=110 PLx Pharma Inc. Reports Fourth Quarter and Full Year 2021 Results and Provides Business Update Momentum Building for Novel Vazalore® Liquid-Filled Aspirin Capsules • Total Net Sales of $8.2 Million in Last Five Months of 2021 • Net Sales of $1.6 Million in the Fourth Quarter 2021, Reflecting Timing of Trade Re-Orders Following Strong Initial Sales Distribution of VAZALORE in the Third Quarter 2021 • Key Performance Measures Are Positive and Trending Higher; Company on Track and Well-Positioned to Grow Sales Substantially in 2022 • GAAP Net Loss of ($0.73) Per Diluted Share in Fourth Quarter 2021; Adjusted Non-GAAP Net Loss Per Diluted Share of ($0.73) • Cash & Cash Equivalent Balance of $69.4 Million at Year-End 2021

https://youtu.be/O_OCb5owR7g TV Werbespot der aktuell in den USA läuft.

https://seekingalpha.com/news/3777793-plx-pharma-gains-after-raymond-james-upgraded-on-valuation

https://zolmax.com/investing/plx-pharma-inc-nasdaqplxp-shares-purchased-by-vanguard-group-inc/6508739.html

PLx Pharma EPS beats by $0.09, beats on revenue https://seekingalpha.com/news/3769940-plx-pharma-eps-beats-0_09-beats-on-revenue?utm_source=webull.com&utm_medium=referral • PLx Pharma (NASDAQ:PLXP): Q3 Non-GAAP EPS of -$0.37 beats by $0.09; GAAP EPS of -$0.80 misses by $0.34. • Revenue of $6.6M beats by $2.5M.

PLx Pharma Inc. Reports Third Quarter 2021 Results and Provides Business Update https://finance.yahoo.com/news/plx-pharma-inc-reports-third-115000911.html -- Results demonstrate strong execution of initial phase of VAZALORE commercial launch, including shipments to 30,000+ stores nationwide and e-commerce sites -- -- Reported net revenue of $6.6 million in third quarter 2021 reflecting initial sales of VAZALORE -- -- Third quarter 2021 net loss was ($0.80) per share and adjusted non-GAAP net loss per share of ($0.37) -- -- Early feedback received from consumers and healthcare professionals is very positive -–

PLx Pharma Inc. Announces New Scientific Data Available Evaluating the Pharmacologic Profile of FDA-Approved VAZALORE 81 mg Liquid-Filled Aspirin Capsules https://finance.yahoo.com/news/plx-pharma-inc-announces-scientific-135000021.html -- VAZALORE 81 mg shows fast bioavailability, absorption, and platelet inhibition -- -- VAZALORE 81 mg has pharmacokinetic and pharmacodynamic profiles consistent with VAZALORE 325 mg -- ...

https://www.analystratings.com/articles/jmp-securities-remains-a-buy-on-plx-pharma-plxp/

PLx Pharma Inc. Provides VAZALORE Launch Update https://www.globenewswire.com/news-release/2021/10/29/2323515/0/en/PLx-Pharma-Inc-Provides-VAZALORE-Launch-Update.html -- Supplied VAZALORE to 30,000+ stores nationwide and e-commerce sites -- -- Launch in line with expectations and exceptionally positive feedback from consumers and healthcare professionals received -- -- Third quarter 2021 earnings and business update conference call scheduled for November 12th -- ...